Solano Wealth Investment Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 8,700 shares of the medical research company's stock, valued at approximately $1,377,000. Natera accounts for approximately 0.8% of Solano Wealth Investment Advisors LLC's investment portfolio, making the stock its 19th biggest position.
Several other hedge funds also recently made changes to their positions in NTRA. Principal Securities Inc. increased its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its stake in shares of Natera by 1.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after purchasing an additional 61 shares during the period. Silver Oak Securities Incorporated boosted its stake in Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after buying an additional 89 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the last quarter. Finally, Hanseatic Management Services Inc. increased its position in Natera by 12.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock worth $158,000 after purchasing an additional 107 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera Price Performance
Shares of NASDAQ NTRA traded up $0.41 during mid-day trading on Monday, reaching $148.45. The company had a trading volume of 887,252 shares, compared to its average volume of 1,394,376. The company has a 50-day moving average price of $152.09 and a two-hundred day moving average price of $152.40. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $20.07 billion, a PE ratio of -84.35 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.
Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.
Analysts Set New Price Targets
A number of brokerages have weighed in on NTRA. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research report on Friday, February 28th. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. Piper Sandler boosted their price objective on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $175.76.
Check Out Our Latest Stock Analysis on NTRA
Insider Transactions at Natera
In other news, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total transaction of $563,120.00. Following the transaction, the director now owns 9,704 shares in the company, valued at $1,366,129.12. This represents a 29.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. This trade represents a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 325,922 shares of company stock valued at $51,603,664. 7.60% of the stock is owned by insiders.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
